Why AstraZeneca’s Olaparib Setback Could Be A Bigger Deal Than It Is
This article was originally published in The Pink Sheet Daily
Executive Summary
Investors don’t have enormous expectations for olaparib in the small subset of ovarian cancer patients AstraZeneca was targeting for accelerated approval, but the negative FDA advisory committee review comes at a pivotal time for the company.